A single-cell framework identifies functionally and molecularly distinct multipotent progenitors in adult human hematopoiesis
- PMID: 40911415
- DOI: 10.1016/j.celrep.2025.116236
A single-cell framework identifies functionally and molecularly distinct multipotent progenitors in adult human hematopoiesis
Abstract
Hematopoietic multipotent progenitors (MPPs) regulate blood cell production to meet the evolving demands of an organism. Adult human MPPs remain ill defined, whereas mouse MPPs are well characterized, with distinct immunophenotypes and lineage potencies. Using multi-omic single-cell analyses and functional assays, we identified distinct human MPPs within Lin-CD34+CD38dim/lo adult bone marrow with unique biomolecular and functional properties. These populations were prospectively isolated based on expression of CD69, CLL1, and CD2 in addition to classical markers like CD90 and CD45RA. We identified a CD69+ MPP with long-term engraftment and multilineage differentiation potential, a CLL1+ myeloid-biased MPP, and a CLL1-CD69- erythroid-biased MPP. We used this updated hematopoietic stem and progenitor cell (HSPC) profile to study human and mouse bone marrow cells and observe unique cell-type-specific homology between species and cell-type-specific changes associated with human aging. By identifying and functionally characterizing adult MPP sub-populations, we provide a framework for future studies in hematopoiesis.
Keywords: CP: Stem cell research; aging; bone marrow; differentiation; hematopoiesis; hematopoietic stem and progenitor cells; hematopoietic stem cells; multipotent progenitors; oligopotent progenitors; single-cell RNA sequencing and single-cell multi-omics.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.M. is on the advisory boards of Kodikaz Therapeutic Solutions, Orbital Therapeutics, Pheast Therapeutics, 858 Therapeutics, Prelude Therapeutics, Mubadala Capital, and Aculeus Therapeutics. R.M. is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics. S.R. and M.N. previously worked at BD Biosciences.
Update of
-
A single cell framework identifies functionally and molecularly distinct multipotent progenitors in adult human hematopoiesis.bioRxiv [Preprint]. 2024 May 10:2024.05.07.592983. doi: 10.1101/2024.05.07.592983. bioRxiv. 2024. Update in: Cell Rep. 2025 Sep 23;44(9):116236. doi: 10.1016/j.celrep.2025.116236. PMID: 38766031 Free PMC article. Updated. Preprint.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous